Also known as: AACR
A deep learning pathomics platform called Path-IO accurately predicted outcomes and immunotherapy response in NSCLC patients using routine pathology slides, outperforming the PD-L1 biomarker. The model was validated across multiple cohorts and improved further when combined with radiomics and clinical data. If validated, it could be easily integrated into clinical workflows.
Alliance launches Phase III trial for stage I NSCLC immunotherapy; Allarity starts Phase 2 SCLC trial. Phase I NSCLC trial sites consolidate at top U.S. sites, prompting FDA representation concerns.
Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.
Only 17.7% of pediatric anticancer drugs advance to phase 3 trials, and just 12% earn FDA approval within 10 years, compared to 38.7% for adult drugs. The pace of pediatric approvals has accelerated recently, but funding and market size constraints remain.
Zai Lab's Q1 2026 revenue fell 6% to $99.6 million, missing expectations, while EPS beat at -$0.05. The company highlighted Zoci intracranial response data and expects three pivotal trials by year-end 2026.
A retrospective study found that myocarditis within the first month after immune checkpoint inhibitor initiation was linked to higher mortality risk. The analysis identified 4,635 cases in VigiBase.
Yale Cancer Center experts presented research at the 2026 AACR Annual Meeting in San Diego, including patient-centered trials, pathology methods and head and neck cancer studies. The meeting also included a plenary presentation, a pathology award and an AACR Trailblazer Cancer Research Grant.
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
Rznomics said it will present interim AACR results for liver cancer candidate RZ-001 from a U.S. trial in patients with hepatocellular carcinoma. Tumor-shrinking responses were observed, and about 23% experienced complete disappearance of cancer cells.
Champions Oncology said it will present eight poster presentations at AACR 2026 in San Diego on April 17-22. The studies cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs and CAR-T therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07723235 |
Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial |
NOT_YET_RECRUITING | NA |
| NCT07663006 |
Breast and Cervical Cancer Stigma in Rwanda |
NOT_YET_RECRUITING | NA |
| NCT07341503 |
The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients |
RECRUITING | |
| NCT07290985 |
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas |
RECRUITING | PHASE2 |
| NCT06298734 |
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial |
RECRUITING | NA |
| NCT04691297 |
Digitally Enhanced Smoking Cessation for High Risk Smokers |
ACTIVE_NOT_RECRUITING | NA |
| NCT04400903 |
Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer |
TERMINATED | |
| NCT04177810 |
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer |
COMPLETED | PHASE2 |
| NCT04005690 |
Targeted Pathway Inhibition in Patients With Pancreatic Cancer |
RECRUITING | EARLY_PHASE1 |
| NCT03520790 |
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer |
TERMINATED | PHASE1 |
